https://www.cdc.gov/drugresistance/biggest_threats.html [accessed July 15, 2017].

D’Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature 2011; 477: 457–461.

Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010; 74: 417–433.

Arzanlou M, Chai WC, Venter H. Intrinsic, adaptive and acquired antimicrobial resistance in Gram-negative bacteria. Essays Biochem. 2017; 61: 49–59.

Tang SS, Apisarnthanarak A, Hsuc LY. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev. 2014; 78: 3–13.

http://www.bldb.eu/ [accessed: July 15, 2017].

Curcio D. Multidrug-resistant Gram-negative bacterial infections: Are you ready for the challenge? Curr Clin Pharmacol. 2014; 9: 27–38.

Mehrad B, Clark NM, Zhanel GG, et al. Antimicrobial resistance in hospital-acquired Gram-negative bacterial infections. Chest 2015; 147: 1413–1421.

Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective Nationwide Surveillance Study. Clin Infect Dis. 2004; 39: 309–317.

Esteban A, Frutos-Vivar F, Ferguson ND, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007; 35: 1284–1289.

Bassetti M, Righi E, Carnelutti A. Bloodstream infections in the Intensive Care Unit. Virulence 2016; 7: 267–279.

Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98: 1826–1835.

Adrie C, Garrouste-Orgeas M, Ibn Essaied W, et al. Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapy. J Infect. 2017; 74: 131–141.

Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18: 268–281.

Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012; 38:1930–1945.

Marín M, Gudiol C, Ardanuy C, et al. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. Clin Microbiol Infect. 2015; 21: 583–590.

Antimicrobial resistance surveillance in Europe 2015. http://www.ecdc.europa.eu

Szücs O, Kristóf K, Darvas K, et al. Changes in the incidence of multiresistant pathogens and its consequences in intensive care unit. [Multirezisztens kórokozók gyakoriságának változása és ennek vonatkozásai az intenzív osztályon.] Orv Hetil. 2011; 152: 1486–1491. [Hungarian]

Infectious Diseases Society of America. The 10 × ‘20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010; 50: 1081–1083.

Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol. 2011; 11: 433–438.

Bassetti M, Righi E. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr Opin Crit Care 2015; 21: 402–411.

Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014; 58: 5350–5357.

Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for infections in an complicated intra-abdominal era of multidrug resistance: Results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015; 60: 1462–1471.

Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385: 1949–1956.

Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016; 56: 56–66.

Dinh A, Wyplosz B, Kernéis S, et al. Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2017; 49: 782–783.

Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012; 28: 1921–1931.

Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016; 16: 661–673.

Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013; 68: 1183–1192.

Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016; 62: 1380–1389.

Torres A, Zhong N, Pachl J, et al. Phase 3, randomized, multicentre study of ceftazidime-avibactam versus meropenem in adults with nosocomial pneumonia including ventilator-associated pneumonia (REPROVE). Abstracts of the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 22–25 April 2017. No OS0603.

Alatoom A, Elsayed H, Lawlor K, et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis. 2017; 62: 39–43.

Taneja N, Kaur H. Insights into newer antimicrobial agents against Gram-negative bacteria. Microbiol Insights 2016; 9: 9–19.

National Center for Epidemiology. Guidelines on prevention of infections caused by multiresistant pathogens. 04.18.2016. [Országos Epidemiológiai Központ. Módszertani levél a multirezisztens kórokozók által okozott fertőzések megelőzéséről. 2016. 04. 18.] http://oek.hu/oek.web [Hungarian]

Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016; 62: e51–e77.